EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study

Masaki Shimizu, Isseki Maeda, Takaomi Kessoku, Hiroto Ishiki, Tetsuya Matsuura, Yusuke Hiratsuka, Yoshinobu Matsuda, Takaaki Hasegawa, Kengo Imai, Shunsuke Oyamada, Eriko Satomi, Phase-R OIC Study Group

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08716-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Masaki Shimizu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Palliative Care, Kyoto-Katsura Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Palliative Care, Neoplasms, Opioid-Induced Constipation, Naltrexone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In this study, we aimed to evaluate the safety and effectiveness of naldemedine for treating opioid-induced constipation (OIC) in patients with advanced cancer, who are receiving palliative care, and particularly explored its early effects. METHODS: Palliative care teams and inpatient palliative care units across 14 institutions in Japan were included in this multicenter, prospective, observational study. Patients who were newly prescribed a daily oral dose of 0.2 mg naldemedine were enrolled. The spontaneous bowel movement (SBM) within 24 h after the first dose of naldemedine was considered the primary outcome, whereas, the secondary outcomes included weekly changes in SBM frequency and adverse events. RESULTS: A total of 204 patients were enrolled and 184 completed the 7-day study. The average age of the participants (103 males, 101 females) was 63 ± 14 years. The primary cancer was detected in the lungs (23.5%), gastrointestinal tract (13.7%), and urological organs (9.3%). A considerable proportion of patients (34.8%) had ECOG performance status of 3-4. Most patients were undergoing active cancer treatment, however, 40.7% of the patients were receiving the best supportive care. Within 24 h of the first naldemedine dose, 146 patients (71.6%, 95% CI: 65.4-77.8%) experienced SBMs. The weekly SBM counts increased in 62.7% of the participants. The major adverse events included diarrhea and abdominal pain, detected in 17.6% and 5.4% of the patients, respectively. However, no serious adverse events were observed. CONCLUSION: Conclusively, naldemedine is effective and safe for OIC treatments in real-world palliative care settings. TRIAL REGISTRATION NUMBER: UMIN000031381, registered 20/02/2018.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Palliative CareNeoplasmsOpioid-Induced ConstipationNaltrexoneAnalgesics, OpioidNarcotic AntagonistsHumansMaleFemaleMiddle AgedProspective StudiesAgedJapanAdultConstipationAged, 80 and overCancer PainTreatment Outcome

Stichwörter der Autor:innen

NaldemedineOpioid-induce constipationReal-world data

Substanzen

naldemedineNaltrexoneAnalgesics, OpioidNarcotic Antagonists

Autor:innen und Institutionen

  • Department of Palliative Care, Kyoto-Katsura Hospital, Kyoto, Japan.
  • Department of Palliative Care, Senri-Chuo Hospital, Toyonaka, Osaka, Japan. Isseki.maeda@gmail.com.
  • Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Japan.
  • Department of Palliative Medicine, International University Health and Welfare Narita Hospital, Narita, Japan.
  • Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Palliative Care Center, Fujisawa Shounandai Hospital, Kanagawa, Japan.

Zitieren

APA

Shimizu, M., Maeda, I., Kessoku, T., Ishiki, H., Matsuura, T., Hiratsuka, Y., Matsuda, Y., Hasegawa, T., Imai, K., Oyamada, S., Satomi, E., & Phase-R OIC Study Group (2024). The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08716-8

Vancouver

Shimizu M, Maeda I, Kessoku T, Ishiki H, Matsuura T, Hiratsuka Y, et al. The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08716-8

BibTeX
@article{Shimizu2024,
  author = {Shimizu, Masaki and Maeda, Isseki and Kessoku, Takaomi and Ishiki, Hiroto and Matsuura, Tetsuya and Hiratsuka, Yusuke and Matsuda, Yoshinobu and Hasegawa, Takaaki and Imai, Kengo and Oyamada, Shunsuke and Satomi, Eriko and Phase-R OIC Study Group, Phase-R OIC Study Group},
  title = {The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08716-8}
}
Kostenlos starten →